Thursday, 13th February 32nd Lorne Cancer 2020

• Malignant Deamination Drives Pre-cancer Stem Cell evolution - Catriona Jamieson
• Unexpected tumour heterogeneity in CLL relapse on venetoclax revealed by single cell analysis - Rachel Thijssen
• Identification of novel tumour suppressor genes in vivo using CRISPR/Cas9 - Shinsuke Mizutani
• RNA splicing alterations induce a cellular stress response associated with poor prognosis in AML - Ashwin Unnikrishnan
• Predicting resistance factors to MCL-1 targeting BH3-mimetic drugs using accurate pre-clinical models of lymphoma - Gemma Kelly

• The Discovery of Paralogous Gene Dependencies in Cancer - William Sellers
• NOVEL EGFRvIII CAR T CELLS ARE AN EFFECTIVE TREATMENT FOR GLIOBLASTOMA - Rebecca C Abbott
• Chromosome arm aneuploidies shape tumour evolution, cancer prognosis and drug response - Ankit Shukla
• Deep profiling by mass cytometry reveals differing T cell activation in ever- and never-smoker lung cancer - Clare Weeden
• DNA barcoding demonstrates immuno-editing of metastatic and non-metastatic breast cancer cells at the clonal level - Simon Junankar
• Identifying co-operative drivers and novel therapeutic targets in SMAD4-deficient oesophageal adenocarcinoma - Julia V Milne
• Using genomics and pre-clinical models to improve treatment options for patients with rare cancers - Holly E Barker
• In vivo imaging of the Akt-FRET biosensor mouse - Max Nobis
• “Immuno-flowFISH”: Next-generation cytogenetic assessment provides unique insight into Chronic Lymphocytic Leukemia - Henry Hui
• BRCA1 mutation stabilises cyclin E1 in breast cancer to create a therapeutically targetable subset - Elizabeth Caldon
• Spliced HLA bound peptides, a new class of antigens for cancer immunotherapy - Pouya Faridi
• Identification of a novel tumour macrophage progenitor - Shweta Tikoo
• Cep55 loss impedes tumorigenesis in vivo - Behnam Rashidieh
• MITF-mediated changes of tumour architecture, tensile stress and in extracellular matrix (ECM) control intratumour heterogeneity in melanoma - Nikolas K Haass
• Cell polarity and tumor organoids for cancer biology and personalized medicine - Senthil Muthuswamy

FLASH TALK POSTERS
 

• NOVEL EGFRvIII CAR T CELLS ARE AN EFFECTIVE TREATMENT FOR GLIOBLASTOMA - Rebecca C Abbott
• Chromosome arm aneuploidies shape tumour evolution, cancer prognosis and drug response - Ankit Shukla
• Deep profiling by mass cytometry reveals differing T cell activation in ever- and never-smoker lung cancer - Clare Weeden
• DNA barcoding demonstrates immuno-editing of metastatic and non-metastatic breast cancer cells at the clonal level - Simon Junankar
• Identifying co-operative drivers and novel therapeutic targets in SMAD4-deficient oesophageal adenocarcinoma - Julia V Milne
• Using genomics and pre-clinical models to improve treatment options for patients with rare cancers - Holly E Barker
• In vivo imaging of the Akt-FRET biosensor mouse - Max Nobis
• “Immuno-flowFISH”: Next-generation cytogenetic assessment provides unique insight into Chronic Lymphocytic Leukemia - Henry Hui
• BRCA1 mutation stabilises cyclin E1 in breast cancer to create a therapeutically targetable subset - Elizabeth Caldon
• Spliced HLA bound peptides, a new class of antigens for cancer immunotherapy - Pouya Faridi
• Identification of a novel tumour macrophage progenitor - Shweta Tikoo
• MITF-mediated changes of tumour architecture, tensile stress and in extracellular matrix (ECM) control intratumour heterogeneity in melanoma - Nikolas K Haass

• CDK4/6 Inhibition: a novel chemosensitizing agent in the treatment of Medulloblastoma  - Christelle Adolphe
• Measuring nano-drug delivery: Development of quantitative visualisation of nanoparticle penetration kinetics in 3D tumour spheroids - Aria Ahmed-Cox
• Linking multi-modal single-cell RNA sequencing with targeted long-read sequencing reveals the clonal and transcriptional profile of lymphocytes - Ghamdan Al-Eryani
• Investigating The role of AIM2 Inflammasome in Lung Adenocarcinoma - Mohammad Alanazi
• Cannabinoids effectively block proliferation of paediatric medulloblastoma cells in vitro - Clara Andradas Arias
• A cellular atlas of treatment-naïve primary prostate cancer generated using single-cell RNA-seq - Eva Apostolov
• Immune modulation using timed-synchronized SBRT-partial tumor irradiation targeting the hypoxic tumor segment (SBRT-PATHY) for global systemic effects - Martin L Ashdown
• Novel role of NEDD4 E3 ligase in exosomes secretion and chemoresistance   - Ishara Atukorala
• Δ40p53 inhibits the p53-mediated response to DNA damaging therapies in breast cancer cells - Luiza Steffens Reinhardt
• Characterising immune evasive sub-clones of 4T1 breast cancer cells to identify new effective breast cancer immunotherapy targets - Louise Baldwin
• Iron overload targeted in glioblastoma using iron-depleted bovine lactoferrin protein - Tulika Basak
• Nucleic acid aptamers as alternative affinity reagents for precision oncology - Michelle Bauer
• Novel Zirconium-89-radiolabelling of therapeutic antibody for the detection of PD-L1 expression by PET imaging - Benjamin Blyth
• Developing a model of high grade serous ovarian carcinoma using CRISPR/Cas9 - Nirashaa T Bound
• Characterisation of molecular response to the RNA polymerase I transcription inhibitor CX-5461 in olaparib-resistant ID8 mouse ovarian cancer cells - Natalie Brajanovski
• Predicting and targeting immune cold breast cancer - Natasha K Brockwell
• CHK1/2 inhibition synergises with radiotherapy in preclinical models of medulloblastoma enabling a reduction in radiation dosage without compromising survival - Jessica Buck
• Exploring Gamma Delta T Cells in Merkel Cell Carcinoma - Alexander Caneborg
• A paracrine activin A–mDia2 axis promotes squamous carcinogenesis via fibroblast reprogramming - Michael Cangkrama
• DCLK1: a novel promoter of gastric cancer progression - Annalisa Carli
• A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death - Sophia Ceder
• The role of calcium channel drugs in lipopolysaccharide (LPS) induced oral cancer cell proliferation - Rajdeep Chakraborty
• Inhibition of the NPY signalling axis as a novel therapeutic option in pancreatic cancer - Cecilia Chambers
• Targeting gp130-dependent cytokine signalling in gastrointestinal cancers - Ashwini Chand
• Successful photodynamic treatment of murine ovarian cancers using Photosoft^TM photosensitising technology - Yiqian Chen
• AXMAP – the Australian pdX MelanomA Project  - Jen G. Cheung
• BMP4 inhibits breast cancer metastasis independent of tumour SMAD4 expression - Lap Hing Chi
• Preclinical assessment of epigenetic therapy using decitabine to treat endocrine-resistant breast cancer - Kee Ming Chia
• Tumor Exosomes: Novel Regulators of Cancer Cachexia - Sai Vara Prasad Chitti
• Histone deacetylase inhibitor as a differentiation therapy for lung adenocarcinoma - Wai Chin Chong
• Identification of RNA splicing therapeutic targets in high-risk paediatric acute leukaemia - Adria Closa
• The clinical utility of circulating tumour DNA in oesophageal cancer - Mariana Corrales Benitez
• Targeting CAF mediated stromal remodeling to disrupt pro-metastatic and chemo-protective tumour microenvironments - Thomas R. Cox
• Examining the impact of FKBP25 knockdown on MDA-MB-468 cell proliferation, invasion and migration. - Tabitha M Cree
• Heterogeneity in single-cell apoptotic signalling promotes chemoresistance in neuroblastoma - David R Croucher
• Circulating antibodies as novel cancer biomarkers - Jessica Da Gama Duarte
• Using patient-derived xenograft models to explore disease - a case report of uterine leiomyosarcoma - Genevieve Dall
• Investigating the impact of nutrient availability on chemotherapy resistance in triple-negative breast cancer - Jasmine V Davis
• Overcoming resistance to PI3K inhibitors in colorectal cancer - Francesc d'Assis de las Heras Vila
• Therapeutic effects of bazedoxifene in combination with chemotherapy in colon cancer - Rhynelle Dmello
• Development of small molecule STING agonists that can evoke host anti-cancer immune defences following local or systemic delivery - Judith Doherty
• c-Myc inactivation of p53 through the pan-cancer lncRNA MILIP drives cancer pathogenesis - Yuchen Feng
• Intestinal Epigenetic Age Determines Risk of Braf Mutant Colorectal Neoplasia  - Lochlan Fennell
• Precision medicine for high-risk paediatric and AYA sarcomas - Emmy Fleuren
• Exosomes containing oncogenic mutant β-catenin activate Wnt signaling pathway in the recipient cells - Pamali Fonseka
• THERAPEUTIC RESTORATION OF IMMUNE SIGNALLING PATHWAYS IN METASTASIS - Miriam Fuentes
• APR-246 targets mitochondrial metabolism through depletion of low-molecular weight thiols  - Kenji Fujihara
• Automated enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma - Kathy Fuller
• Multiple interaction nodes define the post-replication repair response to UV-induced DNA damage that is defective in melanomas and correlated with UV signature mutation load - Brian Gabrielli
• Targeting Mind Bomb-2 and MIP, new Regulators of Tumour cell Survival in TRAIL Signaling - Anna Gabrielyan
•   A functional blood brain barrier is required for the effective translation of novel therapeutic agents for paediatric brain tumours - Laura A Genovesi
• Non-oncogenic addiction to autophagy in breast cancer progression. - Charlett M Giuliani
• Ultra-Rapid and accurate data analysis solution for TSO500 ctDNA: Enabling comprehensive genomic profiling with a plasma-based assay - Gerald Goh
• Loss of ABCB1 predicts for sensitisation to spliceosomal modulation with H3B-8800 – potential implications in the context of monosomy 7 and the myelodysplastic syndromes - Andrew A Guirguis
• Anti-tropomyosin drugs prevent the rescue of vincristine-induced mitotic spindle defects - Peter Gunning
• Uncovering biomechanically regulated cellular processes of melanoma cell invasion and survival in confined environments - Nikolas K Haass
• Bortezomib induces immunogenic cell death in melanoma and enhances immune response in vivo - Nikolas K Haass
• Regorafenib - A TME-modulating RTK inhibitor for the treatment of pancreatic cancer - Tanja Haegele
• Modelling chemotherapy-induced apoptosis to improve response in high-risk neuroblastoma - Jeremy Han
• MRP1 modulators sensitise resistant cancer cells to treatment - Kimberley M Hanssen
• Investigating the Clinical Significance of Fibroblast Growth Factor Inducible 14 in Breast Cancer - Joshua Harris
• Remodeling of metastatic vasculature reduces lung colonisation and sensitises overt metastases to immunotherapy - Bo He
• Identification of novel compounds that induce translational readthrough of nonsense mutant TP53 - Angelos Heldin
• Inhibition of tumour initiation by a novel small molecule compound through reactivating the death response in MYCN-driven cancer - Mika Herath
• Harnessing the innate immune response to treat small cell lung cancer. - Jonas Hess
• Agonizing about antagonizing the androgen receptor in estrogen receptor positive breast cancer - Theresa Hickey
• Network informed analysis of Mucinous Ovarian Carcinoma - Jessica Holien
• ­MicroRNA-based therapeutics for the treatment of high-risk neuroblastoma - Holly Holliday
• Vulnerabilities in glutamine metabolism define triple-negative from Luminal A breast cancer subtypes - Jeff Holst
• Determining the clinical utility of anti-CD47, an immune modulating antibody, as a therapeutic agent in aggressive paediatric brain tumours. - Meegan Howlett
• Developing personalized chemotherapy/targeted treatment for sarcoma patients via PDX testing and patient/tumour/PDX genomic analysis - Evan Ingley
• Interrogating the cell-of-origin of BRCA1 mutant ovarian cancer to inform targeted strategies for cancer prevention - Rachel Joyce
• Cep55 overexpression causes tumorigenesis in mice though multiple mechanisms  - Murugan Kalimutho
• Oncogenic β-catenin regulates partial senescence and secretion of exosomes - Taeyoung Kang
• Visualization of endogenous p27 and Ki67 reveals oxidative phosphorylation-dependent survival of quiescent melanoma cells - Ting La
• CHK1 inhibitor + subclinical dose of hydroxyurea selectively kills melanomas and non-small cell lung cancers in an immunogenic manner, activates the STING pathway and triggers an immunomodulatory response in vivo.  - Brian Gabrielli
• Enhancing the efficacy of microtubule targeting agents through cytoskeletal crosstalk - Sharissa L Latham
• Macrophage-secreted Oncostatin M dictates metastatic potential via functional reprogramming of inflammatory fibroblast polarity in pancreatic ductal adenocarcinoma - Brian Y Lee
• piRNA pathway genes decrease ovarian cancer invasion and can be regulated by gonadotropins - Eunice Lee
• The role of BH-3 mimetic drugs in overcoming immunotherapy resistance in melanoma - ZIZHEN MING
• Robotic-assisted complete mesocolic excision, central vascular ligation and para-aortic lymph node dissection in multifocal carcinoid: A case report and technical description - Rebekah Young
• Robotic complete mesocolic excision using idocyanine fluorescence imaging in colorectal cancer: A case study and technical approach. - Rebekah Young